BioSapien, a California-based biotech company, announced on Friday that it has been nominated by The Galien Foundation, a global institution involved in honouring innovators in life sciences, in the 'Best Startup' category for the 20th Prix Galien USA Awards.

The Prix Galien USA Awards are claimed to recognise innovation, celebrating companies, and technologies with the potential to meaningfully advance human health. Nominees are selected by Awards Committees of biomedical scientists, industry executives and Nobel laureates; from thousands of applications.

BioSapien says that its nomination comes at a pivotal stage in the company's development, as its cancer platform, MediChip, moves toward first-in-human dosing and BioSapien transitions from platform development into clinical validation.

Winners will be announced during the 20th Prix Galien USA Awards Ceremony on 29 October 2026, at the American Museum of Natural History in New York City.